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Abstract
Background: The tripeptide glutathione (L-gamma-glutamyl-cysteinyl-glycine) is essential to cell survival, and deficiency in
cardiac and systemic glutathione relates to heart failure progression and cardiac remodelling in animal models. Accordingly,
we investigated cardiac and blood glutathione levels in patients of different functional classes and with different structural
heart diseases.
Methods: Glutathione was measured using standard enzymatic recycling method in venous blood samples obtained from
91 individuals, including 15 healthy volunteers and 76 patients of New York Heart Association (NYHA) functional class I to IV,
undergoing cardiac surgery for coronary artery disease, aortic stenosis or terminal cardiomyopathy. Glutathione was also
quantified in right atrial appendages obtained at the time of surgery.
Results: In atrial tissue, glutathione was severely depleted (258%) in NYHA class IV patients compared to NYHA class I
patients (P=0.002). In patients with coronary artery disease, this depletion was related to the severity of left ventricular
dysfunction (P=0.006). Compared to healthy controls, blood glutathione was decreased by 21% in NYHA class I patients
with structural cardiac disease (P,0.01), and by 40% in symptomatic patients of NYHA class II to IV (P,0.0001). According to
the functional NYHA class, significant depletion in blood glutathione occurred before detectable elevation in blood sTNFR1,
a marker of symptomatic heart failure severity, as shown by the exponential relationship between these two parameters in
the whole cohort of patients (r=0.88).
Conclusions: This study provides evidence that cardiac and systemic glutathione deficiency is related to the functional
status and structural cardiac abnormalities of patients with cardiac diseases. These data also suggest that blood glutathione
test may be an interesting new biomarker to detect asymptomatic patients with structural cardiac abnormalities.
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Introduction
Despite considerable advances in treatment, heart failure
remains associated with high morbidity and mortality worldwide
[1–3]. Better identification of asymptomatic individuals with
structural cardiac abnormalities would improve outcomes and
reduce incidence of heart failure.
The pro-inflammatory cytokine tumor necrosis factor-alpha
(TNF) and the cleaved extracellular domain of its type-1 receptor
(sTNFR1) are recognized biomarkers of heart failure severity and
adverse outcomes of the disease [4–11]. B-type natriuretic peptide
(BNP) and the amino-terminal fragment of its precursor hormone
(NT-pro-BNP) secreted in response to myocardial stress have also
received considerable attention as potential screening and prognos-
tic tests for symptomatic, New York Heart Association (NYHA)
class II to IV patients [12–16]. However, neither TNF nor sTNFR1
or BNP peptides do help to the screening of asymptomatic patients
suspected of having a structural heart disease. Only very recently,
circulating MMP-9 has been associated with cardiovascular risk
factors in middle-aged normal population [17].
Exacerbated TNF and sTNFR1 expression is related to systemic
and cardiac glutathione deficiency in animal models of heart
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4871failure [18,19], and in advanced heart failing patients [19,20]. In
fact, the antioxidant tripeptide glutathione (L-gamma-glutamyl–
cysteinyl–glycine) is essential for vascular and cardiac function
[19,20], and determines cell survival [21,22].
We hypothesized that functional status and cardiac structural
remodelling of patients were related to glutathione deficiency. The
purpose of the present study was to explore the glutathione levels
in cardiac tissue and blood of patients with cardiac structural
abnormalities in relation to NYHA functional classification, left
ventricular ejection fraction (LVEF) and blood sTNFR1.
Methods
Patients
The study included 76 patients undergoing cardiac surgery
(coronary artery bypass grafting, aortic valve replacement, ortho-
topic heart transplantation and ventricular assist device implanta-
tion) from 2004 to 2007. Clinical data and transthoracic
echocardiographies (Vivid 7, GE, Norway), using american society
of echocardiography recommendations [23], were obtained for all
individuals. To distinguish patients with systolic LV dysfunction
from those with preserved LV function, we used as cut-off value
45% LVEF, which is the mean of the 40–50% range proposed by
the new ESC guidelines [24]. Permanent atrial fibrillation was
defined as long standing atrial fibrillation in which cardioversion
had failed or had been foregone, according to the ESC guidelines
[25]. Venous blood samples and right atrial appendages were
obtained from patients undergoing cardiac surgery for coronary
artery bypass graft or aortic valve replacement with cardiopulmo-
nary bypass. Blood samples only were obtained from patients
undergoing left ventricular assist device implantation. Right atrial
specimen and 2 venous blood samples were taken into cryotubes at
initiation of cardiopulmonary bypass, immediately frozen in liquid
nitrogen and stored at 280uC until use. Patients with sepsis,
endocarditis, renal failure or impaired liver function were excluded.
Fifteen healthy volunteers were recruited by the Centre
d’Investigation Clinique of the Ho ˆpital Henri Mondor. Blood
samples obtained from each fasting volunteer, clinical data, and
transthoracic echocardiographies were processed as described
above for patients. Volunteers included 8 males and 7 females with
mean age of 5264 years (range: 30–70 years), mean LVEF of
61.661.4% (range: 55–68%), mean blood glutathione level of
2.1360.4 (range: 1.84–2.36 mM) and mean blood sTNFR1 level
of 0.2560.01 ng/ml (range: 0.20–0.33 ng/ml).
All patients had given written informed consent before surgical
procedures were performed. All studies are conformed to the
Declaration of Helsinki and were approved by our institutional
ethics committee (AP-HP, Groupe hospitalier Henri-Mondor
Albert-Chenevier, Cre ´teil, F-94010, France).
Assays for glutathione and sTNFR1
Atrial tissue samples were cut into 20 mm sections. Homoge-
nates were prepared from 5 frozen sections of each sample by
homogenization at 4uC, in 200 ml of 50 mM Hepes, pH 7.4,
containing protease inhibitors (1 mM PMSF, 2 mg/ ml leupeptin,
2 mg/ ml aprotinin), using a Qiagen TissueLyzer.
Glutathione was measured in atrial homogenates or whole blood
according to a modification of Tietze’s recycling assay [26] as
previously used [18] and as thoroughly described by Rahman et al.
[27]. In short, it is a spectrophotometric/microplate reader assay
method, relying on oxidation of reduced glutathione (GSH) by the
sulfhydryl reagent 5,59-dithio-bis(2-nitrobenzoic acid) (DTNB) to
form the yellow derivative 59-thio-2-nitrobenzoic acid (TNB),
measurable at 405 nm. Glutathione disulfide (GSSG) is recycled
to GSH by glutathione reductase in the presence of NADPH. This
method is simple, convenient, sensitive, accurate and rapid, and can
assay glutathione in whole blood and tissues. In addition, it uses
sulfosalicylic acid for sample preparation, which inhibits gamma-
glutamyl transferase and limits glutathione loss [27].
sTNFR1 was quantified in whole blood with ELISA kits
(Quantikine, R&D Systems).
Statistical analysis
Results are given as means6sem. Continuous data were
analyzed by Mann-Whitney test or Kruskal-Wallis test combined
with Dunn post-test, as appropriate (Prism, GraphPad Software
Inc). Discontinuous data were analyzed using a Chi square test.
Differences were considered statistically significant at P,0.05 (two
tailed). We determined the cut-off values of blood glutathione and
blood sTNFR1 level to discriminate cardiac patients (NYHA class
I to IV) from healthy controls by constructing receiver operating
characteristics (ROC) curves relating each marker to NYHA class.
Areas under the ROC curves (AUROCs) are given with their 95%
confidence intervals. Cut-off values were chosen to optimize the
couple of values sensitivity/specificity.
Results
Clinical and biological characteristics of the patients
The clinical and biological characteristics of the 76 patients
undergoing surgery for dilated cardiomyopathy (transplantation or
mechanical assist device implantation; n=8), aortic valve stenosis
(AS;n=25) orcoronary artery disease (CAD; n=43) arereported in
Table 1. Patients with CAD and patients with AS constituted the
two principal groups of our cohort. The three groups had cardiac
structural abnormalities. Patients with CAD and patients with
dilated cardiomyopathy had reduced LVEF while AS patients
displayed significant hypertrophy of septal (ST) and posterior (PWT)
end-diastolic walls but preserved LVEF (Table 1). In the cohort,
22% of the patients were of functional NYHAclass I, 31%ofNYHA
class II, 29% of NYHA class III and 18% of NYHA class IV. As
compared to healthycontrols(meanLVEFof6261% and mean age
of 5264 years), patients of NYHA class I had a preserved LVEF
(Fig. 1A). In patients of NYHA class II to IV, LVEF declined
progressively, but only patients of NYHA class III and IV had
statistically depressed LVEF, with mean valuesapproaching 4063%
and 2564%,respectively(Fig. 1A),related to a 3- to 5-foldelevation
in blood sTNFR1 level as compared to healthy controls (Fig. 1B).
Ofnote,meanbloodsTNFR1levelinNYHAclassIpatientswasnot
statistically different from that of healthy controls (Fig. 1B).
Right atrial glutathione in patients with cardiac disease
Compared to patients of NYHA class I, patients of NYHA class
II and III displayed quite preserved right atrial glutathione content
(Fig. 2). In contrast, patients of NYHA class IV demonstrated a
dramatic 58% depletion in atrial tissue glutathione, dropping to
1.060.2 nmol glutathione/mg tissue to be compared to
2.460.2 nmol glutathione/mg tissue in NYHA class I patients
(P=0.002) (Fig. 2). Of note, as previously pointed out by Carnes
et al [28], patients with permanent atrial fibrillation displayed a
significant decrease in atrial glutathione content compared to
patients with sinus rhythm (1.160.3 vs 2.160.2 nmol/ mg tissue,
respectively; P,0.05) (Table 1).
Next, we considered separately the two principal CAD and AS
groups of patients, redistributed into 2 subgroups according to their
LV function, after excluding patients with permanent atrial
fibrillation. The subgroup of CAD patients with LVEF decline
(#45%) displayed 40% deficiency in atrial glutathione content
Glutathione in Heart Diseases
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(1.7260.2 vs 2.960.4 nmol glutathione/mg tissue, respectively;
Fig. 3A). Indeed, atrial glutathione in CAD patients was positively
correlated with LVEF (r=0.48, P=0.007) (Fig. 3B). In contrast,
atrial glutathione content in AS patients was rather low, indepen-
dently of the LV function (2.260.5 and 2.460.3 nmol glutathione/
mg tissue for .45% and #45% LVEF, respectively; Fig. 3A).
Blood glutathionedeficiencyinpatientswithcardiac disease
Compared to healthycontrols, patients of NYHAclass I displayed
a significant 21% decrease in blood glutathione (P,0.0001)
(Fig. 4A). Compared to patients of NYHA class I, patients of
NYHA class II to IV displayed larger depletion in blood glutathione
(P=0.005) with a mean 40% decrease below the control value
(P,0.0001). When considering separately the two CAD and AS
groups of patients, blood glutathione level was found significantly
lowerthan that ofhealthycontrols,independentlyofthe LVEFvalue
(Fig. 4B).The decrease in blood glutathione was exponentially
correlated with the increase in blood sTNFR1 level in the whole
cohort of patients (r=0.88; Fig. 5). Interestingly, significant
depletion in blood glutathione occurred before detectable elevation
in blood sTNFR1. To examine, whether or not ageing might
influence our findings, patients were divided into two groups,
younger patients (#65 years) and older patients (.65 years). The
Table 1. Baseline characteristics of patients undergoing cardiac surgery.
Parameters All patients CAD AS P-value
Demographic
Male/ female (n/ n) 60/ 16 37/ 6 15/ 10 0.01
Age (years) 66616 2 627 5 62 ,0.0001
NYHA (mean) 2.360.1 2.260.2 2.660.2 NS
NYHA class I (%) 22 31 5
NYHA class II (%) 31 31 42
NYHA class III (%) 29 26 37
NYHA class IV (%) 18 12 16
Clinical
Hypertension (%) 56 64 36 NS
Hypercholesterolemia (%) 56 81 47 0.03
Diabetes mellitus (%) 35 45 17 NS
Permanent atrial fibrillation (%) 12 5 24 0.01
Echocardiographic
LVEF (%) 45624 5 625 3 64 0.06
LVEDD (mm) 54615 5 625 0 62 0.04
iLVEDD (mm.cm
22) 30613 0 612 9 61N S
ST (mm) 11.660.4 10.360.4 13.360.7 0.0001
PWT (mm) 10.860.4 9.860.4 12.160.6 0.002
LA diameter (mm) 41624 1 624 2 63N S
Systolic PAP (mm Hg) 44624 2 644 3 63N S
Medication
Beta-blockers (%) 51 71 22 0.0005
ACE inhibitors (%) 35 50 11 NS
AT-II type 1 R antagonists (%) 21 20 22 NS
Diuretics (%) 48 43 57 NS
Aldosterone antagonists (%) 16 20 9 NS
Statin (%) 60 77 35 0.001
Surgical
Not urgent surgery, n(%) 83 81 100 0.02
Biochemical
CRP (mg/ l) 11621 1 631 1 66N S
Haemoglobin (g/ dl) 13.160.2 13.360.3 12.860.5 NS
Total bilirubin (mg/ dl) 17621 8 631 7 63N S
Creatinine (mmol/ l) 106651 0 9 68 10066N S
CAD: patients with coronary artery diseases; AS: patients with aortic valve stenosis; LVEF: left ventricular ejection fraction; LVEDD: left ventricular end diastolic diameter;
iLVEDD: indexed LVEDD; ST: end-diastolic septal wall thickness; PWT: end-diastolic posterior wall thickness; LAD: left atrial diameter; PAP: pulmonary artery pressure;
CRP: C-reactive protein. In CAD and AS, blood glutathione was not correlated with the age (p=0.46). Data are given as mean or percentage 6sem. P-values refer to the
comparisons between CAD and AS patients.
doi:10.1371/journal.pone.0004871.t001
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approaching 1.561 mM in younger patients (#65 years, mean age
of 5561y e a r s )a n d1 . 4 60.1 mM in older patients (.65 years, mean
age of 7461 years). The relation between blood glutathione and
sTNFR1 persisted whatever the age of the patients was (Fig. 5).
ROC curve analysis for discriminating NYHA class I–IV
patients from healthy controls was done for each sTNFR1 and
blood glutathione marker. The optimal cut-off value of sTNFR1
level was 0.33 ng/ml with an AUROC-95%CI: 0.95 [0.9–1], a
sensitivity of 85.5% and a specificity of 100%. The optimal cut-off
value of blood glutathione level was 1.835 mM with an AUROC-
95%CI: 0.94 [0.89–0.99], a sensitivity of 81.5% and a specificity of
100%. Using these thresholds, the composite index {glutathio-
ne,1.835 mM or sTNFR1$0.33 nmol/ml} vs {glutathio-
ne$1.835 mM and sTNFR1,0.33 nmol/ml} discriminated be-
tween patients and controls with an improved sensitivity of 88.7%
and a conserved 100% specificity. This result confirms the
complementarity between both markers for discriminating patients
from healthy controls. In fact, blood glutathione decrease allowed
identification of NYHA class I patients from controls, whereas a
large increase in blood sTNFR1 characterized patients of NYHA
class IV.
Discussion
The new findings of our study are twofold. Firstly, asymptom-
atic patients of NYHA I class display significantly deficiency in
blood glutathione level compared to healthy controls. Blood
glutathione deficiency worsens in patients of NYHA class II to IV
in relation to blood sTNFR1 elevation, a marker of heart failure.
Secondly, glutathione content in the atrial tissue is diminished by
58% in NYHA class IV patients compared to NYHA class I
patients, and the degree of its decrease in CAD patients correlates
with LVEF decline.
To our knowledge, our study is the first to show that blood
glutathione deficiency correlates with the severity of heart failure
symptoms in patients. Oxidative stress is a recognized contributor
to heart failure progression [29,30], and previous studies have
pointed out changes in the redox status of glutathione in the failing
heart. However, they have overlooked a possible deficiency in total
glutathione content [31]. The originality of the present study was
to investigate this issue in a context of identifying a possible marker
of cardiac disease severity with possible implication in clinical
stratification.
sTNF and its receptors sTNFR1 and sTNFR2 are pro-
inflammatory molecules, the blood levels of which are associated
with oxidative stress and are predictive of heart failure adverse
outcomes [4,6,9,11]. In keeping with previous reports, we observe
a progressive increase in blood sTNFR1 level with increasing
NYHA class in our patients. Blood sTNFR1 was inversely and
exponentially correlated with blood glutathione, illustrating the
Figure 1. Relations between LVEF or blood sTNFR1 level and
NYHA class in cardiac patients and healthy controls. The cohort
displayed standard relations between functional NYHA class and LVEF
(A) or blood sTNFR1 level (B). LVEF: left ventricular ejection fraction.
sTNFR1: cleaved extracellular domain of TNFR1. Linear trends P,0.0001.
*P,0.05 vs healthy controls (C). {P,0.05 vs NYHA class I; {P,0.05 vs
NYHA class II; $P,0.05 vs NYHA class III.
doi:10.1371/journal.pone.0004871.g001
Figure 2. Relation between atrial tissue glutathione content
and NYHA class in cardiac patients. Atrial tissue glutathione
content was significantly decreased in symptomatic patients of NYHA
class IV compared to asymptomatic patients of NYHA class I. *P,0.05 vs
NYHA class I.
doi:10.1371/journal.pone.0004871.g002
Glutathione in Heart Diseases
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disease. One may also note that deficiency in systemic glutathione
in cardiac patients occurs well before the drop in cardiac tissue
glutathione. Several studies provide evidence for a close
relationship between blood glutathione decrease and the patho-
genesis of different inflammatory chronic diseases [22,32]. In fact,
systemic glutathione provides many tissues in the body, and its
deficiency is likely to affect vital functions including resistance to
oxidative stress, mitochondrial function and integrity, immune
response and cell survival [33]. In the cardiac myocyte,
glutathione deficiency fuels a vicious TNF/ sTNFR1/ oxidative
stress/ neutral sphingomyelinase/ apoptosis cycle [18,19,34–36].
Accordingly, early deficiency in systemic glutathione is likely to
contribute to the progression of the cardiac disease.
We have previously reported that LV of patients with end-stage
cardiomyopathies, undergoing orthotopic heart transplant or
ventricular assist device, is depleted by 54% in gluthatione
compared to control LV [19]. In the present study, we have used
atrial appendage as a surrogate for LV tissue. We recognize that
atrium does not undergo same physiological requests and stresses
as the LV. However, atrial appendage is accessible in patients with
a large range of symptoms and with different cardiac diseases.
Interestingly atrial glutathione content is depleted by 58% in
NYHA class IV patients compared with NYHA class I patients,
which is a drop similar to that found in end-stage failing LV. A
previous study has also reported that hemodynamic impairment in
both right and left ventricles of patients with heart failure
subsequent to myocardial infarction correlates with a decrease in
glutathione antioxidant efficiency [31]. Accordingly in the present
study, LVEF decline is associated with atrial glutathione deficiency
Figure 3. Atrial tissue glutathione content in patients with
coronary artery diseases (CAD) or aortic stenosis (AS),
according to preserved LVEF (.45%) or depressed LVEF
(#45%). Patients with permanent atrial fibrillation were excluded. (A)
Deficiency in atrial tissue glutathione was related to LV dysfunction in
CAD patients. In contrast, atrial glutathione was rather low in AS
patients, independently of the LVEF value. *P,0.05 vs LVEF.45%. (B) In
CAD patients, atrial tissue glutathione content correlated significantly
with the LVEF value (r=0.45, P=0.006).
doi:10.1371/journal.pone.0004871.g003
Figure 4. Blood glutathione level in cardiac patients and in the
subgroups of patients with coronary artery diseases (CAD) or
aortic stenosis (AS). (A) In patients undergoing cardiac surgery, the
decrease in blood glutathione level was related to NYHA class (linear
trend P,0.0001). (B) Compared to healthy controls, blood glutathione
level in the CAD and AS subgroups of patients was depleted,
independently of the LVEF value. *P,0.05 vs healthy controls (C);
{P,0.05 vs NYHA class I.
doi:10.1371/journal.pone.0004871.g004
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display equal atrial glutathione content, independently of the
LVEF value. Indeed, the latter experience early LV remodelling
related to increased intra-cardiac pressures and without marked
LVEF decline. Finally, in agreement with the previous observation
made by Carnes et al. [28], we found a 50% decrease in atrial
glutathione content in patients with permanent atrial fibrillation
compared to other patients with sinus rhythm, which is also
consistent with the decreased incidence of postoperative atrial
fibrillation observed after intravenous supplementation with the
glutathione precursor, N-acetylcysteine (NAC) [37]. Taken
together, these results suggest that glutathione deficiency impinges
on the whole damaged heart. They also suggest that glutathione
supplementation may improve cardiac cell preservation in cardiac
diseases, and be a complement to contemporary treatments.
It should be mentioned that the present study is limited by the
relatively small cohort size. In addition, although our results
provide some evidence that the concomitant use of blood
glutathione and blood sTNFR1 tests may improve the sensitivity
of cardiac patient diagnostic, further comparison between blood
glutathione and biomarkers of heart failure other than sTNFR1, in
particular serum BNP peptides, is needed. Indeed, this was not
possible in the present study in which only frozen blood samples
were available. The present study did not either examine the
prognostic impact of blood glutathione.
In conclusion, although further studies are needed to verify the
diagnostic and/ or predictive value of blood glutathione in heart
failure as a part of a multi marker panel test, this study provides
evidence that cardiac and systemic glutathione deficiency is related
with the functional status and the structural cardiac abnormalities
of patients with cardiac diseases. These data also encourage the
development of blood glutathione test as a possible new diagnostic
tool for detecting asymptomatic patients with structural cardiac
abnormalities.
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